Zobrazeno 1 - 10
of 145
pro vyhledávání: ''
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
BMC Cancer
BMC Cancer
Background Oral mucositis (OM) associated with cancer treatment not only impairs patients’ quality of life but also causes treatment delays or changes. This prospective exploratory study was conducted to evaluate the efficacy of Episil® oral liqui
Autor:
Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Yoshinori Okubo, Jun Nakamura, Mika Takasumi, Minami Hashimoto, Tsunetaka Kato, Ryoichiro Kobashi, Takuto Hikichi, Hiromasa Ohira
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer
BMC Cancer
Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemother
Autor:
Tarek Hashem, Chandrasekhar Chikatapu, Bivas Biswas, Yoke Fui Wong, K. Slimane, Ravindran Kanesvaran, Sara Ingles, Mustafa Erman, Chun Sen Lim, Lingwu Chen, Hsiao-Jen Chung, Bulent Karabulut, P. Danchaivijitr
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background Clinical effectiveness and safety data of pazopanib in patients with advanced or mRCC in real-world setting from Asia Pacific, North Africa, and Middle East countries are lacking. Methods PARACHUTE is a phase IV, prospective, non-intervent
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-5 (2021)
BMC Cancer
BMC Cancer
Background Chemotherapy induced nausea- vomiting (CINV) is considered as the most common, feared and most troublesome side effect of chemotherapy. NEPA (NEtupitant 300 mg + PAlonosetron 0.50 mg) is the first commercially available oral fixed-dose com
Autor:
Annemarie C. Eggen, Geke A. P. Hospers, Ingeborg Bosma, Miranda C. A. Kramer, Anna K. L. Reyners, Mathilde Jalving
Publikováno v:
BMC Cancer, 22(1):247. BMC
Background Effective systemic treatments have revolutionized the management of patients with metastatic melanoma, including those with brain metastases. The extent to which these treatments influence disease trajectories close to death is unknown. Th
Autor:
van Eijk, Maarten, Vermunt, Marit A. C., van Werkhoven, Erik, Wilthagen, Erica A., Huitema, Alwin D. R., Beijnen, Jos H.
Publikováno v:
BMC Cancer
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Background Administration of single-agent docetaxel in a weekly schedule may offer similar efficacy, with a more favorable toxicity profile, compared to a three-weekly schedule in patients with metastatic breast cancer. Methods The original search of
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
BMC Cancer
BMC Cancer
Background To explore the maximum tolerated dose (MTD) and evaluate the safety of dose escalation using hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) concurrent with chemotherapy for unresectable stage III
Autor:
Andrew F. Nyein, Shahla Bari, Stephanie Hogue, Yayi Zhao, Bradley Maller, Sybil Sha, Maria F. Gomez, Dana E. Rollison, Lary A. Robinson
Publikováno v:
BMC Cancer
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Background Treatment outcomes of advanced non-small cell lung cancer (NSCLC) have substantially improved with immune checkpoint inhibitors (ICI), although only approximately 19% of patients respond to immunotherapy alone, increasing to 58% with the a
Autor:
Isabelle Ghelerter, Marie-Hélène Lafeuille, Adriana C Rossi, Philippe Thompson-Leduc, Shuchita Kaila, Ming-Hui Tai, Patrick Lefebvre, Kathleen Gray, Shebli Atrash
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
Background Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherapy and combination therapy across several indications, both among newly-diagnosed and refractory patients with multiple myeloma (MM). However, there is limited
Autor:
Umesh Jayarajah, Matthew Jalink, Sanjeeva Gunasekera, Hasitha Promod, Sanjeewa Seneviratne, Christopher M. Booth, Don Thiwanka Wijeratne
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Background Although breast cancer is the most common cancer among Sri Lankan women, there is little published data on patient characteristics and treatment in the local context. We aimed to describe disease characteristics and management in a large c